Literature DB >> 9226314

Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck.

D M Brizel1, G S Sibley, L R Prosnitz, R L Scher, M W Dewhirst.   

Abstract

PURPOSE: Tumor hypoxia adversely affects short term clinical radiation response of head and neck cancer lymph node metastases and long term disease-free survival (DFS) in cervix carcinoma. This study was performed to evaluate the relationship between tumor hypoxia and DFS in patients with squamous carcinoma of the head and neck (SCCHN). METHODS AND MATERIALS: Pretreatment tumor pO2 was assessed polarographically in SCCHN patients. All patients were AJCC Stage IV and had pretreatment oxygen measurements taken from locally advanced primaries (T3 or T4) or neck nodes > or = 1.5 cm diameter. Treatment consisted of once daily (2 Gy/day to 66-70 Gy) or twice daily irradiation (1.25 Gy B.I.D. to 70-75 Gy) +/- planned neck dissection (for > or = N2A disease) according to institutional treatment protocols.
RESULTS: Twenty-eight patients underwent tumor pO2 measurement. The average pre-treatment median pO2 was 11.2 mm Hg (range 0.4-60 mm Hg). The DFS at 12 months was 42%. The DFS was 78% for patients with median tumor pO2 > 10 mm Hg but only 22% for median pO2 < 10 mm Hg (p = 0.009). The average tumor median pO2 for relapsing patients was 4.1 mm Hg and 17.1 mm Hg in non-relapsing (NED) patients (p = 0.007).
CONCLUSION: Tumor hypoxia adversely affected the prognosis of patients in this study. Understanding of the mechanistic relationship between hypoxia and treatment outcome will allow for the development of new and rational treatment programs in the future.

Entities:  

Mesh:

Year:  1997        PMID: 9226314     DOI: 10.1016/s0360-3016(97)00101-6

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  290 in total

Review 1.  Management of the clinically negative (N0) neck.

Authors:  Karen T Pitman; Robert Dean
Journal:  Curr Oncol Rep       Date:  2002-01       Impact factor: 5.075

2.  DNA damage measured by the comet assay in head and neck cancer patients treated with tirapazamine.

Authors:  M J Dorie; M S Kovacs; E C Gabalski; M Adam; Q T Le; D A Bloch; H A Pinto; D J Terris; J M Brown
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

3.  Exposure to acute hypoxia induces a transient DNA damage response which includes Chk1 and TLK1.

Authors:  Isabel M Pires; Zuzana Bencokova; Chris McGurk; Ester M Hammond
Journal:  Cell Cycle       Date:  2010-07-01       Impact factor: 4.534

Review 4.  Imaging tumor hypoxia to advance radiation oncology.

Authors:  Chen-Ting Lee; Mary-Keara Boss; Mark W Dewhirst
Journal:  Antioxid Redox Signal       Date:  2014-03-24       Impact factor: 8.401

Review 5.  The clinical utility of imaging methods used to measure hypoxia in cervical cancer.

Authors:  Joseph Waller; Benjamin Onderdonk; Ann Flood; Harold Swartz; Jaffer Shah; Asghar Shah; Bulent Aydogan; Howard Halpern; Yasmin Hasan
Journal:  Br J Radiol       Date:  2020-04-22       Impact factor: 3.039

6.  Hypoxia in renal disease with proteinuria and/or glomerular hypertension.

Authors:  Tetsuhiro Tanaka; Toshio Miyata; Reiko Inagi; Toshiro Fujita; Masaomi Nangaku
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

7.  Anthracycline inhibits recruitment of hypoxia-inducible transcription factors and suppresses tumor cell migration and cardiac angiogenic response in the host.

Authors:  Tetsuhiro Tanaka; Junna Yamaguchi; Kumi Shoji; Masaomi Nangaku
Journal:  J Biol Chem       Date:  2012-08-20       Impact factor: 5.157

Review 8.  Cytoglobin in tumor hypoxia: novel insights into cancer suppression.

Authors:  Sankalpa Chakraborty; Rince John; Alo Nag
Journal:  Tumour Biol       Date:  2014-05-10

Review 9.  Linking the history of radiation biology to the hallmarks of cancer.

Authors:  Mary-Keara Boss; Robert Bristow; Mark W Dewhirst
Journal:  Radiat Res       Date:  2014-05-08       Impact factor: 2.841

Review 10.  Imaging tumour hypoxia with oxygen-enhanced MRI and BOLD MRI.

Authors:  James P B O'Connor; Simon P Robinson; John C Waterton
Journal:  Br J Radiol       Date:  2019-01-24       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.